Invention Grant
- Patent Title: Heterocyclic compound and application thereof
-
Application No.: US16635408Application Date: 2018-08-02
-
Publication No.: US11319286B2Publication Date: 2022-05-03
- Inventor: Tatsuhiko Fujimoto , Kentaro Rikimaru , Koichiro Fukuda , Hiromichi Sugimoto , Takahiro Matsumoto , Yuichi Kajita , Satoshi Mikami , Yuhei Miyanohana , Tatsuki Koike , Masaki Daini , Masaki Ogino , Kohei Takeuchi , Tohru Miyazaki , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: JPJP2017-150683 20170803
- International Application: PCT/JP2018/029045 WO 20180802
- International Announcement: WO2019/027003 WO 20190207
- Main IPC: C07D207/14
- IPC: C07D207/14 ; C07D401/14 ; C07D403/06 ; A61P25/28
Abstract:
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Information query
